Articles

Optimizing Treatment Approaches Following CDK4/6 Inhibitor Resistance

SABCS 2025 - ER+/HER2- Breast Cancer

Explore cutting-edge strategies and emerging therapies designed to tackle resistance after CDK4/6 inhibitor progression in advanced breast cancer. Read More ›

Emerging Endocrine Therapies

SABCS 2025 - ER+/HER2- Breast Cancer

Discover how oral SERDs and innovative combination therapies are reshaping breast cancer treatment, offering new hope for patients with advanced and resistant disease. Read More ›

Videos

Zongertinib in HER2-Mutant NSCLC With Brain Metastases: Findings From the Beamion LUNG-1 Trial

By Stephanie McDonald, FNP-BC, AOCNP

WCLC 2025 - Non-Small Cell Lung Cancer

Zongertinib shows promising efficacy in patients with brain metastases in pretreated HER2-mutant non−small cell lung cancer Read More ›

Videos

Clinical Outcomes in HER2-Mutant NSCLC Treated With Sevabertinib: Insights From the SOHO-01 Phase 1/2 Trial

By Stephanie McDonald, FNP-BC, AOCNP

WCLC 2025 - Non-Small Cell Lung Cancer

Sevabertinib demonstrates promising efficacy and manageable safety in pretreated HER2-mutant non−small cell lung cancer (NSCLC) patients Read More ›

Videos

monarchE and NATALEE: Key Outcomes in HR-Positive/HER2-Negative Early Breast Cancer

By Sara M. Tolaney, MD, MPH

ESMO 2025 - Early Breast Cancer

In this video, Dr Sara Tolaney underscores the positive overall survival outcomes from the monarchE trial, reinforcing the impact of adjuvant abemaciclib plus endocrine therapy in high-risk, hormone receptor (HR)-positive/HER2-negative early breast cancer, while also noting the sustained 5-year benefits observed with ribociclib and nonsteroidal aromatase inhibitors in the NATALEE trial. Read More ›

Wrap-Up

Sacituzumab Govitecan vs Chemotherapy in Advanced Triple-Negative Breast Cancer: Results From the ASCENT-03 Phase 3 Study

ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer

This ASCENT-03 Phase 3 study compared sacituzumab govitecan with chemotherapy in patients with previously untreated advanced TNBC who are ineligible for PD-L1 inhibitors, demonstrating potential efficacy and safety in this challenging population. Read More ›

Wrap-Up

First Clinical Data of DB-1305/BNT325 (TROP2 ADC) in Pretreated TNBC: Phase 1/2 Efficacy and Safety Insights

ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer

This phase 1/2 trial presents the first clinical data on DB-1305/BNT325, a TROP2-targeting antibody–drug conjugate, demonstrating efficacy and safety in patients with pretreated triple-negative breast cancer. Read More ›

Wrap-Up

Patient-Reported Outcomes in ASCENT-04/KEYNOTE-D19: Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in PD-L1–positive Metastatic Triple-Negative Breast Cancer

ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The phase 3 ASCENT-04/KEYNOTE-D19 trial evaluated patient-reported outcomes comparing sacituzumab govitecan plus pembrolizumab with chemotherapy plus pembrolizumab in previously untreated PD-L1–positive metastatic TNBC, offering insights into quality of life and symptom management. Read More ›

Wrap-Up

Low-Dose Pembrolizumab With Anthracycline and Taxane in Triple-Negative Breast Cancer: Results From a Randomized Controlled Trial

ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer

This trial evaluated the addition of low-dose pembrolizumab to neoadjuvant anthracycline and taxane regimens, revealing potential synergy in triple-negative breast cancer. Read More ›

Wrap-Up

Novel MUC1-C ADC Demonstrates Potent Antitumor Activity in Triple-Negative Breast Cancer

ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer

This study highlights the remarkable antitumor potency of a novel MUC1-C ADC, offering a promising therapeutic option for patients with triple-negative breast cancer. Read More ›

Articles

Page 4 of 143